Literature DB >> 12401833

Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases.

L Huang, Y Y Cheng, L T C Chow, M H Zheng, S M Kumta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12401833      PMCID： PMC1769799          DOI： 10.1136/jcp.55.11.877

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  9 in total

1.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Osteoprotegerin and rank ligand expression in prostate cancer.

Authors:  J M Brown; E Corey; Z D Lee; L D True; T J Yun; M Tondravi; R L Vessella
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

4.  Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors:  R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

5.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 6.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Authors:  T Suda; N Takahashi; N Udagawa; E Jimi; M T Gillespie; T J Martin
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

Review 7.  Biology of osteoclast activation in cancer.

Authors:  G D Roodman
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

Review 8.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases.

Authors:  J M Chirgwin; T A Guise
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2000       Impact factor: 1.807

9.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205
  9 in total
  21 in total

1.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

2.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 3.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

4.  RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.

Authors:  J T Ney; T Fehm; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-05       Impact factor: 2.915

Review 5.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

6.  Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

Authors:  Aaron L Sabbota; Hyeong-Reh Choi Kim; Xiaoning Zhe; Rafael Fridman; R Daniel Bonfil; Michael L Cher
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.

Authors:  Kelsi Andrade; Jaime Fornetti; Ling Zhao; Scott C Miller; R Lor Randall; Neysi Anderson; Susan E Waltz; Mark McHale; Alana L Welm
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

8.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  ADAM17 mRNA expression and pathological features of hepatocellular carcinoma.

Authors:  Xiang Ding; Lian-Yue Yang; Gen-Wen Huang; Wei Wang; Wei-Qun Lu
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

Review 10.  Role of RANKL/RANK in primary and secondary breast cancer.

Authors:  Toshiyuki Yoneda; Soichi Tanaka; Kenji Hata
Journal:  World J Orthop       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.